Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

The B.C. government is restricting the sales of two more diabetes drugs to people outside Canada amid rising demand for the ...

NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...